The implosion of Zygel’s fragile X study leaves its developer few places to turn.
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.
By pricing remdesivir at $2,340 for a five-day course Gilead has kept investors on side, but others will be disappointed.
The company blasts the US regulator as weeks of uncertainty for its lead drug in Nash end in a complete response letter.
But a licensing deal with CSL could have underappreciated benefits, even if expectations were for something much bigger.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
The rivals have taken different strategies with next-gen pneumococcal vaccines, which will be fighting for a blockbuster market that is Pfizer’s to lose.
The cash-and-stock deal, worth $886m up front, is the first major liquid biopsy acquisition since Roche bought Foundation Medicine.
The deal-hungry French big pharma gives Translate’s mRNA vaccine technology a massive boost.